ALF MEEM YAA FOR MEDICAL SUPPLIES AND EQUIPMENT COMPANY
(A SAUDI JOINT STOCK COMPANY)

UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS AND INDEPENDENT AUDITOR'S REVIEW REPORT

FOR THE THREE-MONTH AND SIX-MONTH PERIODS ENDED 30 JUNE 2026

ALF MEEM YAA FOR MEDICAL SUPPLIES AND EQUIPMENT COMPANY
(A SAUDI JOINT STOCK COMPANY)
UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS
FOR THE THREE-MONTH AND SIX-MONTH PERIODS ENDED 30 JUNE 2026

Table of contents **Page**

Independent auditor’s review report on the unaudited interim condensed financial statements	1
Unaudited interim condensed statement of financial position	2
Unaudited interim condensed statement of profit or loss and other comprehensive income	3
Unaudited interim condensed statement of changes in equity	4
Unaudited interim condensed statement of cash flows	5
Notes to the unaudited interim condensed financial statements	6 - 21

EY
Shape the future with confidence

Ernst & Young Professional Services (Professional LLC)
Paid-up capital (⃁5,500,000 – Five million five hundred thousand Saudi Riyal)

King's Road Tower, 13th Floor, King Abdul Aziz Road (Malek Road)
P.O. Box 1994, Jeddah 21441
Kingdom of Saudi Arabia, Head Office – Riyadh
C.R. No.: 1010383821, Unified No.: 7000117205

C.R. No. (Jeddah Branch):
4030276644

Tel: +966 12 221 8400
Fax: +966 12 664 4408

ey.ksa@sa.ey.com
ey.com

INDEPENDENT AUDITOR'S REVIEW REPORT ON THE UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS TO THE SHAREHOLDERS OF ALF MEEM YAA FOR MEDICAL SUPPLIES AND EQUIPMENT COMPANY (A SAUDI JOINT STOCK COMPANY)

Introduction:

We have reviewed the accompanying unaudited interim condensed statement of financial position of Alf Meem Yaa for Medical Supplies and Equipment Company (A Saudi Joint Stock Company) (the "Company") as at 30 June 2026, and the related unaudited interim condensed statements of profit or loss and other comprehensive income for the three-month and six-month periods ended 30 June 2026, and the related unaudited interim condensed statements of changes in equity and cash flows for the six-month period then ended, and explanatory notes. Management is responsible for the preparation and presentation of these unaudited interim condensed financial statements in accordance with International Accounting Standard 34, "Interim Financial Reporting" ("IAS 34") as endorsed in the Kingdom of Saudi Arabia. Our responsibility is to express a conclusion on these unaudited interim condensed financial statements based on our review.

Scope of Review:

We conducted our review in accordance with International Standard on Review Engagements 2410, "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*" as endorsed in the Kingdom of Saudi Arabia. A review of interim financial statement consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing that are endorsed in the Kingdom of Saudi Arabia and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion:

Based on our review, nothing has come to our attention that causes us to believe that the accompanying unaudited interim condensed financial statements are not prepared, in all material respects, in accordance with IAS 34 that are endorsed in the Kingdom of Saudi Arabia.

for Ernst & Young Professional Services

Abdulaziz S. Alarifi
Certified Public Accountant
License No. (572)

J14
EY
سجل تجاري ٤٠٣٠٢٧٦٦٤٤
CR 4030276644
شركة إرنست ويونغ للخدمات المهنية
(مهنية ذات مسؤولية محدودة)
Ernst & Young Professional Services
(Professional LLC)

Jeddah: 18 Rabi Al-Awwal 1448H
(31 August 2026G)

ALF MEEM YAA FOR MEDICAL SUPPLIES AND EQUIPMENT COMPANY
(A SAUDI JOINT STOCK COMPANY)

UNAUDITED INTERIM CONDENSED STATEMENT OF FINANCIAL POSITION
As at 30 June 2026

	Notes	***30 June 2026 (Unaudited) SR***	*31 December 2025 (Audited) SR*
ASSETS			
NON-CURRENT ASSETS			
Property and equipment	4	**1,821,680**	2,206,847
Right-of-use assets	5	**564,577**	728,869
Intangible assets		**1,830,281**	2,096,496
Installment sales receivables – non-current portion	7	**3,843,628**	1,416,687
TOTAL NON-CURRENT ASSETS		**8,060,166**	6,448,899
CURRENT ASSETS			
Inventories	6	**108,394,995**	109,039,872
Installment sales receivables – current portion	7	**47,145,514**	46,409,446
Trade receivables	8	**106,321,858**	91,254,167
Prepayments and other assets	9	**14,259,091**	11,613,107
Cash and cash equivalents	10	**22,078,239**	9,743,740
TOTAL CURRENT ASSETS		**298,199,697**	268,060,332
TOTAL ASSETS		**306,259,863**	274,509,231
EQUITY AND LIABILITIES			
EQUITY			
Share capital		**70,000,000**	70,000,000
Reserve		**5,040,698**	5,040,698
Retained earnings		**117,106,779**	104,144,344
TOTAL EQUITY		**192,147,477**	179,185,042
LIABILITIES			
NON-CURRENT LIABILITIES			
Employee benefits		**14,148,896**	13,292,474
Lease liabilities – non-current portion	12	**199,809**	377,060
TOTAL NON-CURRENT LIABILITIES		**14,348,705**	13,669,534
CURRENT LIABILITIES			
Trade payables		**19,347,423**	10,212,018
Bank borrowings	13	**25,440,041**	27,046,820
Accrued expenses and other liabilities	11	**33,240,372**	36,478,871
Lease liabilities – current portion	12	**355,294**	349,962
Zakat payable	14	**7,380,551**	7,566,984
Dividend payable		**14,000,000**	-
TOTAL CURRENT LIABILITIES		**99,763,681**	81,654,655
TOTAL LIABILITIES		**114,112,386**	95,324,189
TOTAL EQUITY AND LIABILITIES		**306,259,863**	274,509,231

Chief Financial Officer

Chief Executive Officer

Chairman of the Board

The accompanying notes from 1 to 24 form an integral part of these unaudited interim condensed financial statements.

ALF MEEM YAA FOR MEDICAL SUPPLIES AND EQUIPMENT COMPANY
(A SAUDI JOINT STOCK COMPANY)

UNAUDITED INTERIM CONDENSED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

For the three-month and six-month periods ended 30 June 2026

		Three-month period ended 30 June		*Six-month period ended 30 June*	
	Notes	***2026***	*2025*	***2026***	*2025*
		SR	*SR*	***SR***	*SR*
			(Restated)		*(Restated)*
Revenue	15	**65,123,115**	68,139,806	**170,807,695**	161,476,365
Cost of revenue	16	**(41,314,500)**	(38,720,357)	**(105,089,494)**	(91,223,395)
GROSS PROFIT		**23,808,615**	29,419,449	**65,718,201**	70,252,970
Selling and marketing expenses	17	**(9,387,254)**	(6,014,214)	**(22,770,288)**	(18,087,055)
General and administrative expenses	18	**(5,155,796)**	(10,098,891)	**(15,038,957)**	(17,314,317)
Reversal of expected credit losses - trade receivables		**1,752,698**	927,555	**1,599,271**	392,993
Allowance for expected credit losses – instalment sale receivables		**(252,783)**	(4,404,313)	**(899,271)**	(4,861,825)
Other income		**485,474**	16,434	**957,773**	1,186,844
OPERATING PROFIT		**11,250,954**	9,846,020	**29,566,729**	31,569,610
Finance cost		**(764,021)**	(1,277,291)	**(1,208,273)**	(2,378,337)
Finance income		**826,940**	762,686	**972,541**	1,018,027
PROFIT BEFORE ZAKAT		**11,313,873**	9,331,415	**29,330,997**	30,209,300
Zakat expense	14.1	**(1,386,409)**	(1,023,331)	**(2,736,409)**	(2,304,060)
PROFIT FOR THE PERIOD		**9,927,464**	8,308,084	**26,594,588**	27,905,240
OTHER COMPREHENSIVE INCOME / (LOSS)					
Items not to be reclassified to statement of profit or loss in subsequent periods:					
Actuarial gain / (loss) on re-measurement of employee benefits		**367,847**	(739,616)	**367,847**	(739,616)
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD		**10,295,311**	7,568,468	**26,962,435**	27,165,624
EARNINGS PER SHARE:					
Earnings per share attributable to shareholders of the Company (SR)					
- Basic and diluted	19	**1.42**	1.19	**3.80**	3.99

Chief Financial Officer   Chief Executive Officer   Chairman of the Board

The accompanying notes from 1 to 24 form an integral part of these unaudited interim condensed financial statements.

UNAUDITED INTERIM CONDENSED STATEMENT OF CHANGES IN EQUITY

For the six-month period ended 30 June 2026

	Share capital SR	*Reserve SR*	*Retained earnings SR*	*Total SR*
At 1 January 2025	70,000,000	5,040,698	83,788,650	158,829,348
Profit for the period	-	-	27,905,240	27,905,240
Other comprehensive loss for the period	-	-	(739,616)	(739,616)
Total comprehensive income for the period	-	-	27,165,624	27,165,624
Dividends paid	-	-	(14,000,000)	(14,000,000)
At 30 June 2025 (unaudited)	70,000,000	5,040,698	96,954,274	171,994,972
At 1 January 2026	70,000,000	5,040,698	104,144,344	179,185,042
Profit for the period	-	-	**26,594,588**	**26,594,588**
Other comprehensive income for the period	-	-	**367,847**	**367,847**
Total comprehensive income for the period	-	-	**26,962,435**	**26,962,435**
Dividends paid	-	-	**(14,000,000)**	**(14,000,000)**
At 30 June 2026 (unaudited)	**70,000,000**	**5,040,698**	**117,106,779**	**192,147,477**

Chief Financial Officer

Chief Executive Officer

Chairman of the Board

The accompanying notes from 1 to 24 form an integral part of these unaudited interim condensed financial statements.

ALF MEEM YAA FOR MEDICAL SUPPLIES AND EQUIPMENT COMPANY
(A SAUDI JOINT STOCK COMPANY)

UNAUDITED INTERIM CONDENSED STATEMENT OF CASH FLOWS
For the six-month period ended 30 June 2026

	Notes	***2026 (Unaudited) SR***	*2025 (Unaudited) SR*
OPERATING ACTIVITIES			
Profit before zakat		**29,330,997**	30,209,300
Adjustments to reconcile profit before zakat to net cash flows:			
Depreciation of property and equipment	4	**425,094**	387,124
Depreciation of right of use assets	5	**164,292**	470,985
Amortisation of intangible asset		**266,215**	216,655
Reversal of losses on financial assets - trade receivables	8	**(1,599,271)**	(392,993)
Impairment of losses on financial assets – instalment sale receivables	7	**899,271**	4,861,825
Provision for slow moving inventories	6	**407,834**	637,442
Provision for employee benefits		**1,286,769**	1,072,063
Lease adjustment		**-**	(469,310)
Finance cost		**1,208,273**	1,504,858
		32,389,474	38,497,949
Working capital changes:			
Decrease / (increase) in inventories		**237,043**	(3,046,633)
Increase in installment sales receivables		**(4,062,280)**	(16,487,015)
Increase in trade receivables		**(13,468,420)**	(15,479,364)
Increase in prepayments and other current assets		**(2,645,985)**	(10,881,362)
Increase in trade payables		**9,135,405**	2,845,562
Increase in contract liabilities		**-**	16,515
(Decrease) / increase in accrued expenses and other current liabilities		**(3,238,498)**	1,679,335
Cash from / (used in) operations		**18,346,739**	(2,855,013)
Zakat paid		**(2,922,842)**	(2,051,233)
Employee benefits paid		**(62,500)**	(61,334)
Finance costs paid		**(1,208,273)**	(647,547)
Net cash flows from / (used in) operating activities		**14,153,124**	(5,615,127)
INVESTING ACTIVITIES			
Purchase of property and equipment	4	**(39,927)**	(422,132)
Purchase of intangible asset		**-**	(610,301)
Net cash flows used in investing activities		**(39,927)**	(1,032,433)
FINANCING ACTIVITIES			
Proceed from bank borrowing		**16,632,524**	46,018,128
Repayment of bank borrowing		**(18,239,303)**	(237,006)
Repayment of lease liability		**(171,919)**	(733,022)
Dividends paid		**-**	(13,986,342)
Net cash flows (used in) / from financing activities		**(1,778,698)**	31,061,758
Net increase in cash and cash equivalents		**12,334,499**	24,414,198
Cash and cash equivalents at the beginning of the period		**9,743,740**	24,211,581
CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD		**22,078,239**	48,625,779

Chief Financial Officer	Chief Executive Officer	Chairman of the Board

The accompanying notes from 1 to 24 form an integral part of these unaudited interim condensed financial statements.

1 CORPORATE INFORMATION

Alf Meem Yaa for Medical Supplies and Equipment Company (the “Company") is a Saudi Joint Stock Company incorporated in Jeddah, Kingdom of Saudi Arabia. The Company was registered as a Saudi Limited liability company on 14 Safar 1430H, corresponding to 9 February 2009, under commercial registration number 4030186415 and Unified identification number 7001587315.

On 23 Jumada I 1443H, corresponding 27 December 2021, the Capital Market Authority (CMA) has approved the registration of the Company shares for the purpose of direct listing on Numu - Parallel Market. The shares of the Company are listed on Nomu - Parallel Market and start trading as on 15 Jumada Al Thani 1443H, corresponding to 18 January 2022 with the symbol 9527 and ISIN Code SA15GGP4KRH1.

As per the Company’s By-laws, the Company is engaged in wholesale and retail trade which mainly includes perfumes, cosmetics, orthotic devices, medical supplies, decorative soap, incense, veterinary medicine and medical equipment.

The Company operates through the following branches and these unaudited interim condensed financial statements include their results as well:

Branch / City	*Commercial Registration No.*	*Registration Date*
Riyadh	1010478367	12 Rabie Awal 1440H, corresponding to 19 November 2018
Jeddah	4030186415	14 Safar 1430H, corresponding to 9 February 2009
Dammam	2050133577	8 Rajab 1441H, corresponding to 3 March 2020

The registered address of the Company is Prince Sultan Street P.O. Box 11544, Jeddah 21463 Kingdom of Saudi Arabia

2 BASIS OF PREPARATION

2.1 Statement of compliance

The unaudited interim condensed financial statements for the six-month period ended 30 June 2026 have been prepared in accordance with International Accounting Standard 34 - Interim Financial Reporting (“IAS 34”) as endorsed in the Kingdom of Saudi Arabia as well as other standards and pronouncements that are endorsed by Saudi Organization for Chartered and Professional Accountants (“SOCPA”). The Company has prepared the unaudited interim condensed financial statements on the basis that it will continue to operate as a going concern. The Board of Directors consider that there are no material uncertainties that may cast significant doubt over this assumption. They have formed a judgement that there is a reasonable expectation that the Company has adequate resources to continue in operational existence for the foreseeable future, and not less than 12 months from the end of the reporting period.

The unaudited interim condensed financial statements do not include all the information and disclosures required in the annual financial statements and should be read in conjunction with the Company’s annual financial statements for the year ended 31 December 2025 (see also note 2.4). In addition, results for the three-month and six-month period ended 30 June 2026 are not necessarily indicative of the results for the year ending 31 December 2026.

2.2 Basis of measurement

These unaudited interim condensed financial statements are prepared under the historical cost convention.

2.3 Functional and presentation currency

These unaudited interim condensed financial statements are presented in Saudi Riyals (SR), which is the Company’s functional and presentation currency.

2 BASIS OF PREPARATION (continued)

2.4 Material accounting judgements, estimates and assumptions

The preparation of the Company's unaudited interim condensed financial statements requires management to make judgments, estimates and assumptions that affect the reported amounts of revenues, expenses, assets, liabilities and accompanying disclosures. The key assumptions concerning the future and other key sources of estimation uncertainty at the reporting date, that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial period, were disclosed in annual financial statements for the year ended 31 December 2025. Any future change in the assumptions and estimates could result in outcomes that could require a material adjustment to the carrying amounts of the assets or liabilities affected in the future periods.

2.5 Material accounting policies

The accounting policies adopted by the Company for the preparation of these unaudited interim condensed financial statements are consistent with those followed in preparation of the Company's annual financial statements for the year ended 31 December 2025, except for accounting policies related to the new standard adopted by the Company effective as of 1 January 2026 (see note 3).

3 NEW STANDARDS, INTERPRETATIONS AND AMENDMENTS ADOPTED BY THE COMPANY

The accounting policies adopted in the preparation of the unaudited interim condensed financial statements are consistent with those followed in the preparation of the Company's annual financial statements for the year ended 31 December 2025, except for the adoption of new standards effective as of 1 January 2026. The Company has not early adopted any standard, interpretation or amendment that has been issued but is not yet effective.

- Classification and Measurement of Financial Instruments – Amendments to IFRS 9 and IFRS 7
- Annual Improvements to IFRS Accounting Standards – Volume 11
- Contracts Referencing Nature-dependent Electricity – Amendments to IFRS 9 and IFRS 7

The amendments had no impact on Company's interim condensed financial statements.

3.1 Expected impact of the initial application of IFRS 18 ("Presentation and Disclosure in Financial Statements")

In April 2024, the International Accounting Standards Board ("IASB") issued IFRS 18 Presentation and Disclosure in Financial Statements, which replaces IAS 1 Presentation of Financial Statements and becomes effective for annual reporting periods beginning on or after 1 January 2027. The new standard introduces new requirements and updates to the statement of profit or loss, with the main objective of improving comparability in the statement of profit or loss and enhancing transparency over management-defined performance measures.

The key new concepts introduced by IFRS 18 include:

- A revised structure of the statement of profit or loss, requiring classification of income and expenses into 5 defined categories based on the entity's main business activities and presentation of mandatory subtotals;
- Enhanced principles on aggregation and disaggregation which apply to the primary financial statements and notes in general; and
- Required disclosures in the financial statements for certain profit or loss performance measures that are reported outside an entity's financial statements (that is, management-defined performance measures).

The Company is in the process of assessing the estimated impact that the initial application of IFRS 18 will have on its financial statements.

3.1.1 Structure of the Statement of Profit or Loss

The standard is expected to result in changes to the presentation of certain line items and subtotals in the statement of profit or loss namely operating, investing, financing, zakat/income tax and discontinued operations. This classification depends on the main business activities of the entity.

The adoption of IFRS 18 is not expected to affect the Company's profit for the period or total equity. IFRS 18 primarily affects the presentation and disclosure of information in the financial statements rather than the recognition and measurement of assets, liabilities, income and expenses. However, IFRS 18 introduces mandatory subtotals, including:

- Operating profit; and
- Profit or loss before financing and income taxes.

3 NEW STANDARDS, INTERPRETATIONS AND AMENDMENTS ADOPTED BY THE COMPANY (continued)

3.1 Expected impact of the initial application of IFRS 18 ("Presentation and Disclosure in Financial Statements") (continued)

3.1.1 Structure of the Statement of Profit or Loss (continued)

The Company is currently assessing the presentation of income and expense items within the new categories and subtotals required by IFRS 18. Based on the information currently available, the Company expects changes to the presentation and classification of certain items within the statement of profit or loss. Interest expense arising from borrowings is expected to be presented within the financing category in accordance with the requirements of IFRS 18.

The Company currently presents foreign exchange gains and losses within finance (loss) / income. Under IFRS 18, foreign exchange differences are generally classified in the same category as the income and expenses arising from the underlying transactions, assets or liabilities that generated those differences. Accordingly, the Company expects certain foreign exchange differences to be presented within the operating category and others within the financing category, depending on the nature of the underlying item. For example, foreign exchange differences arising from trade receivables and trade payables are expected to be presented within the operating category, while foreign exchange differences arising from borrowings, if any, are expected to be presented within the financing category.

The Company continues to assess the detailed classification requirements of IFRS 18 and the resulting impact on the presentation of its statement of profit or loss.

3.1.2 Aggregation and disaggregation

IFRS 18 introduces enhanced requirements for the aggregation and disaggregation of information presented in the primary financial statements and disclosed in the notes. The standard also provides additional guidance regarding the labelling and description of line items.

The Company is currently assessing how the new requirements may affect the presentation and disclosure of information within its financial statements. This assessment includes evaluating whether additional disaggregation of certain balances and transactions may be required and whether existing descriptions and labels continue to provide useful information to users of the financial statements.

The Company is also reviewing items currently aggregated within captions such as "others" to determine whether more specific descriptions or further disaggregation may be required under IFRS 18.

3.1.3 Management performance measures “MPMs”

IFRS 18 introduces disclosure requirements for management-defined performance measures ("MPMs"). MPMs are subtotals of income and expenses that are used in public communications outside the financial statements and communicate management's view of a particular aspect of the Company's financial performance as a whole.

Where applicable, IFRS 18 requires entities to disclose specified information about MPMs in a single note to the financial statements, including reconciliations to the most directly comparable subtotal specified by IFRS Accounting Standards.

The Company is currently assessing whether any measures used in its public communications meet the definition of management-defined performance measures and, if applicable, will provide the disclosures required by IFRS 18.

3.1.4 Consequential amendments

IFRS 18 includes consequential amendments to IAS 7 Statement of Cash Flows. These amendments require entities applying the indirect method to use operating profit, as defined by IFRS 18, as the starting point for the reconciliation of operating cash flows.

The Company currently uses profit before zakat as the starting point for this reconciliation. Accordingly, certain reconciling items within the statement of cash flows are expected to change following the adoption of IFRS 18.

Based on its preliminary assessment of the consequential amendments to IAS 7, the Company expects interest paid to be classified within financing activities. The Company is continuing to assess the classification of interest received and the related presentation of cash flows associated with deposits and other treasury activities.

The Company is continuing to assess the impact of these amendments on the presentation of its statement of cash flows and the related disclosures.

4 PROPERTY AND EQUIPMENT

	Furniture *SR*	*Leasehold improvements & fixtures* *SR*	*Computers* *SR*	*Office equipment* *SR*	*Tools* *SR*	*Motor vehicles* *SR*	*Total* *SR*
Cost:							
At 1 January 2026	841,634	1,930,921	931,320	416,870	43,835	727,680	4,892,260
Additions	-	-	**12,642**	**27,285**	-	-	**39,927**
At 30 June 2026	**841,634**	**1,930,921**	**943,962**	**444,155**	**43,835**	**727,680**	**4,932,187**
Accumulated depreciation:							
At 1 January 2026	465,486	1,080,781	509,693	211,180	28,245	390,028	2,685,413
Charge for the period	**75,430**	**180,875**	**61,399**	**39,736**	**2,994**	**64,660**	**425,094**
At 30 June 2026	**540,916**	**1,261,656**	**571,092**	**250,916**	**31,239**	**454,688**	**3,110,507**
Net book value:							
At 30 June 2026 (unaudited)	**300,718**	**669,265**	**372,870**	**193,239**	**12,596**	**272,992**	**1,821,680**

4 PROPERTY AND EQUIPMENT (continued)

	Furniture *SR*	*Leasehold improvements & fixtures* *SR*	*Computers* *SR*	*Office equipment* *SR*	*Tools* *SR*	*Motor vehicles* *SR*	*Total* *SR*
Cost:							
At 1 January 2025	751,596	1,930,921	628,961	337,545	27,835	462,115	4,138,973
Additions	90,038	-	302,359	79,325	16,000	265,565	753,287
At 31 December 2025	841,634	1,930,921	931,320	416,870	43,835	727,680	4,892,260
Accumulated Depreciation:							
At 1 January 2025	319,816	712,728	402,714	145,768	24,920	278,804	1,884,750
Charge for the year	145,670	368,053	106,979	65,412	3,325	111,224	800,663
At 31 December 2025	465,486	1,080,781	509,693	211,180	28,245	390,028	2,685,413
Net book value:							
At 31 December 2025 (audited)	376,148	850,140	421,627	205,690	15,590	337,652	2,206,847

The depreciation charged during the period / year is allocated to general and administrative expenses.

5 RIGHT-OF-USE ASSETS

The Company has lease agreements for buildings. The Company also has lease agreements for warehouses with lease terms of 12 months or less. The Company applies the 'short-term lease' and 'lease of low-value assets' recognition exemptions for these leases.

The movement of right of use assets is as follows:

	30 June 2026 (Unaudited) SR	*31 December 2025 (Audited) SR*
At the beginning of the period / year	**728,869**	1,113,758
Adjustment	**-**	(53,586)
Depreciation charged for the period / year	**(164,292)**	(331,303)
At the end of the period / year	**564,577**	728,869

The depreciation charged during the period / year is allocated to general and administrative expenses.

6 INVENTORIES

	30 June 2026 (Unaudited) SR	*31 December 2025 (Audited) SR*
Medical equipment	**23,240,534**	13,806,967
Medical supplies	**87,428,683**	92,952,839
Stock in transit	**-**	2,689,846
Return asset	**1,183,066**	2,639,674
	111,852,283	112,089,326
Less: provision for slow moving inventory	**(3,457,288)**	(3,049,454)
	108,394,995	109,039,872

6.1 Movement in the provision for slow moving inventories is as follows:

	30 June 2026 (Unaudited) SR	*31 December 2025 (Audited) SR*
Balance at the beginning of the period / year	**3,049,454**	2,157,649
Addition during the period / year	**407,834**	891,805
Balance at the end of period / year	**3,457,288**	3,049,454

7 INSTALLMENT SALES RECEIVABLES

Installments sales receivables comprise of receivables arising from sales of medical equipment. For the purposes of these interim condensed financial statements, installment sales receivables pertaining to sale of medical equipment are carried at amortized cost, as detailed below:

	30 June 2026 (Unaudited) SR	*31 December 2025 (Audited) SR*
Gross installment sales receivable	**65,687,929**	61,516,418
Less: Unearned finance income	**(1,283,965)**	(1,174,734)
Installment sales receivable	**64,403,964**	60,341,684
Less: allowance for expected credit loss	**(13,414,822)**	(12,515,551)
Net installment sales receivable	**50,989,142**	47,826,133

7.1 Movement in the allowance for expected credit loss is as follows:

	30 June 2026 (Unaudited) SR	*31 December 2025 (Audited) SR*
Balance at the beginning of the period / year	**12,515,551**	6,790,662
Charge for the period / year	**899,271**	5,724,889
Balance at the end of period / year	**13,414,822**	12,515,551

The Company applies a simplified approach for calculating expected credit losses prescribed by IFRS 9, which permits the use of the lifetime expected loss for all receivable balance. Based on the historical trend and expected performance of the customers, the Company believes that the above expected credit loss allowance sufficiently covers the risk of default.

The ageing of instalment sales receivables is as follows:

Ageing	***Gross carrying amount***	***Expected credit loss range (%)***	***Loss allowance***
At 30 June 2026:			
Within the credit period	**31,028,331**	**1.96%**	**607,948**
1-90 days past due	**7,497,543**	**10.55%**	**791,269**
91-180 days past due	**6,770,587**	**14.23%**	**963,165**
181- 270 days past due	**4,555,879**	**18.62%**	**848,236**
271- 360 days past due	**2,832,412**	**24.47%**	**693,090**
More than 1 year past due	**13,003,177**	**73.14%**	**9,511,114**
Total	**65,687,929**		**13,414,822**

7 INSTALLMENT SALES RECEIVABLES (continued)

Ageing	*Gross carrying amount*	*Expected credit loss range (%)*	*Loss allowance*
At 31 December 2025:			
Within the credit period	32,950,514	2.40%	790,707
1-90 days past due	7,045,857	12.21%	860,305
91-180 days past due	5,270,820	16.61%	875,700
181- 270 days past due	3,011,139	21.56%	649,164
271- 360 days past due	1,502,307	27.73%	416,541
More than 1 year past due	11,735,781	76.03%	8,923,134
Total	61,516,418		12,515,551

8 TRADE RECEIVABLES

Trade receivables comprise the following:

	30 June 2026 (Unaudited) SR	*31 December 2025 (Audited) SR*
Trade receivables	**120,335,314**	106,866,894
Less: Allowance for expected credit loss	**(14,013,456)**	(15,612,727)
Net trade receivables	**106,321,858**	91,254,167

8.1 Movement in the allowance for expected credit loss is as follows:

	30 June 2026 (Unaudited) SR	*31 December 2025 (Audited) SR*
Balance at the beginning of the period / year	**15,612,727**	5,062,572
Reversal / charge for the period / year	**(1,599,271)**	10,550,155
Balance at the end of period / year	**14,013,456**	15,612,727

The Company applies a simplified approach for calculating expected credit losses prescribed by IFRS 9, which permits the use of the expected lifetime loss for all receivable balance. Based on the historical trend and expected performance of the customers, the Company believes that the above expected credit loss allowance sufficiently covers the risk of default.

8 TRADE RECEIVABLES (continued)

Aging analysis of trade receivable is as follows:

Ageing	***Gross carrying amount***	***Expected credit Loss range (%)***	***Loss allowance***
At 30 June 2026:			
Within the credit period	**70,688,314**	**0.96%**	**678,369**
1-90 days past due	**19,762,400**	**4.45%**	**879,489**
91-180 days past due	**8,531,637**	**9.98%**	**851,267**
181- 270 days past due	**2,796,262**	**18.20%**	**509,014**
271- 360 days past due	**2,319,514**	**26.29%**	**609,793**
More than 1 year past due	**16,237,188**	**64.58%**	**10,485,524**
Total	**120,335,314**		**14,013,456**

Ageing	*Gross carrying amount*	*Expected credit loss range (%)*	*Loss allowance*
At 31 December 2025:			
Within the credit period	62,459,442	1.47%	915,489
1-90 days past due	9,792,391	6.12%	598,889
91-180 days past due	9,053,555	13.33%	1,207,106
181- 270 days past due	6,316,327	23.91%	1,510,304
271- 360 days past due	3,155,122	32.75%	1,033,277
More than 1 year past due	16,090,057	64.31%	10,347,662
Total	106,866,894		15,612,727

9. PREPAYMENTS AND OTHER ASSETS

	30 June 2026 (Unaudited) SR	*31 December 2025 (Audited) SR*
Advances to suppliers	**7,548,710**	6,423,384
VAT receivable	**3,989,707**	2,761,405
Employees' loans	**645,080**	904,282
Prepaid insurance	**586,090**	419,322
Prepaid rent	**646,129**	276,467
Bank guarantee	**34,000**	34,000
Others	**809,375**	794,247
	14,259,091	11,613,107

10 CASH AND CASH EQUIVALENTS

	30 June 2026 (Unaudited) SR	*31 December 2025 (Audited) SR*
Cash in hand	**309,855**	69,333
Cash at bank	**21,768,384**	9,674,407
	22,078,239	9,743,740

The cash at bank is held in current accounts with banks having sound credit ratings. The credit risk on these balances is expected to be very minimal. Bank balances are subject to an insignificant risk of changes in value. The fair value of cash and cash equivalents approximates the carrying value at 30 June 2026 and 31 December 2025.

11 ACCRUED EXPENSES AND OTHER LIABILITIES

	30 June 2026 (Unaudited) SR	*31 December 2025 (Audited) SR*
Staff incentive accruals	**13,454,531**	10,258,285
Marketing related accruals	**12,990,250**	15,830,244
Refund liabilities	**1,963,086**	4,388,710
Intangible asset related accrual	**2,095,936**	2,095,936
Advances from customers	**614,533**	1,675,060
Accrual related to committee and board members	-	1,239,916
Warranty assurance	**546,855**	532,720
Others	**1,575,181**	458,000
	33,240,372	36,478,871

12 LEASE LIABILITIES

Movement in lease liabilities is summarized as follows:

	30 June 2026 (Unaudited) SR	*31 December 2025 (Audited) SR*
At the beginning of the period / year	**727,022**	1,626,122
Accretion of interest	**23,081**	65,189
Adjustment	-	(574,289)
Payments made during the period / year	**(195,000)**	(390,000)
At the end of the period / year	**555,103**	727,022

12 LEASE LIABILITIES (continued)

The scheduled maturities of the lease liabilities are as follows:

As at 30 June 2026 (unaudited)	***30 June 2026 (Unaudited) SR***	*31 December 2025 (Audited) SR*
Current portion	**355,294**	349,962
Non-current portion	**199,809**	377,060
	555,103	727,022

12.1 Expenses related to short-term and low-value leases for the period ended 30 June 2026 amounted to SR 881,588 (30 June 2025: SR 409,365).

13 SHORT TERM BORROWINGS

In 2025, the Company obtained multi-purpose credit facilities from a commercial bank to support its operational and capital expenditure requirements. The facilities comprise a short-term Murabaha facility with a limit of SR 50 million, bearing a profit margin of SAIBOR + 2.3%, utilized to finance the Company's operating cycle. As at 30 June 2026, the outstanding balance under this facility amounted to SR 25.4 million. A revolving financing facility with a limit of SR 20 million, bearing a profit margin of SAIBOR + 2.5%, intended to finance the cost of equipment. As at 30 June 2026, there was no outstanding balance under this facility. The financing facilities are secured by a promissory note issued by the Company.

The outstanding financing is classified under current liabilities in the statement of financial position, as these facilities are repayable within 12 months from the reporting date.

The breakup of the bank facilities is as follows:

	30 June 2026 (Unaudited) SR	*31 December 2025 (Audited) SR*
Short term facility	**25,440,041**	27,046,820

14 ZAKAT

Zakat is charged at the higher of net adjusted income or Zakat base as required by the ZATCA. The key elements of zakat base primarily include equity components, net income and liabilities adjusted for zakat purpose.

14.1 Provision for zakat

	30 June 2026 (Unaudited) SR	*31 December 2025 (Audited) SR*
At the beginning of the period/ year	**7,566,984**	8,000,600
Provision for the current period / year	**2,736,409**	4,813,876
Reversal related to prior years	-	(1,096,459)
Payments during the period / year	**(2,922,842)**	(4,151,033)
At the end of the period / year	**7,380,551**	7,566,984

14 ZAKAT (continued)

14.2 Status of assessments

The Company filed its Zakat returns with the Zakat, Tax and Customs Authority ("ZATCA") up to the year ended 31 December 2025 and settled the Zakat liabilities in accordance with the submitted returns. The Company has obtained a Zakat certificate valid until 30 April 2027.

The review and examination for the financial years ended 31 December 2020 to 2024 have been completed by ZATCA. Any Zakat differences assessed for these years have been settled by the Company, and no outstanding liabilities remain in respect of those years. For the financial year ended 31 December 2025, the zakat assessment is under review by ZATCA.

15 REVENUE

Disaggregation of revenues from contracts with customers

In the following table, revenue from contracts with customers is disaggregated by primary geographical market, major products and services lines and timing of revenue recognition.

15.1 By primary geographical markets

The revenue from contracts with customers is derived from the primary geographical market that is the Kingdom of Saudi Arabia.

15.2 By major products/service lines

The Company has determined that it operates as a single reportable segment, revenues at 30 June 2026 and 30 June 2025 comprise from the following:

	Three-month period ended		***Six-month period ended***	
	30 June 2026 (Unaudited) SR	*30 June 2025 (Unaudited) SR*	***30 June 2026 (Unaudited) SR***	*30 June 2025 (Unaudited) SR*
Medical supplies	**52,854,158**	49,726,100	**139,617,003**	121,328,826
Medical equipment sales with significant financing	**10,767,390**	16,873,452	**28,221,290**	36,459,535
Supplier of services	**1,501,567**	1,540,254	**2,969,402**	3,688,004
	65,123,115	68,139,806	**170,807,695**	161,476,365

15.3 By timing of revenue recognition

	Three-month period ended		***Six-month period ended***	
	30 June 2026 (Unaudited) SR	*30 June 2025 (Unaudited) SR*	***30 June 2026 (Unaudited) SR***	*30 June 2025 (Unaudited) SR*
Products transferred at a point in time	**65,123,115**	68,139,806	**170,807,695**	161,476,365

16 COST OF REVENUE

	Three-month period ended		Six-month period ended	
	30 June 2026 (Unaudited) SR	30 June 2025 (Unaudited) SR	**30 June 2026 (Unaudited) SR**	30 June 2025 (Unaudited) SR
Cost of goods sold	**41,220,131**	38,197,046	**103,946,396**	90,332,784
Cost of service – employees' related cost	**94,369**	523,311	**1,143,098**	890,611
	41,314,500	38,720,357	**105,089,494**	91,223,395

17 SELLING AND MARKETING EXPENSES

	Three-month period ended		Six-month period ended	
	30 June 2026 (Unaudited) SR	30 June 2025 (Unaudited & Restated) SR	**30 June 2026 (Unaudited) SR**	30 June 2025 (Unaudited & Restated) SR
Staff incentive and marketing expenses	**4,078,905**	1,496,171	**14,060,877**	9,174,072
Employees' cost	**5,240,094**	4,400,002	**8,548,876**	8,728,024
Transportation and freight charges	**68,255**	118,041	**160,535**	184,959
	9,387,254	6,014,214	**22,770,288**	18,087,055

18 GENERAL AND ADMINISTRATIVE EXPENSES

	Three-month period ended		Six-month period ended	
	30 June 2026 (Unaudited) SR	30 June 2025 (Unaudited & Restated) SR	**30 June 2026 (Unaudited) SR**	30 June 2025 (Unaudited & Restated) SR
Employees' cost	**533,578**	6,378,992	**7,278,361**	10,478,417
Early payment discount	**986,112**	-	**1,839,563**	-
Legal and professional fees	**617,983**	1,275,158	**1,062,619**	2,456,967
Subscription expenses	**863,834**	530,564	**1,423,001**	1,021,793
Board of Directors and audit committee remuneration	**360,000**	556,000	**360,000**	556,000
Depreciation of right-of-use-assets	**82,601**	320,585	**164,292**	470,985
Rent expenses	**457,613**	227,212	**881,588**	409,365
Depreciation of property and equipment	**212,406**	197,504	**425,094**	387,124
Amortisation of intangible asset	**133,108**	108,327	**266,215**	216,655
Audit fees	**449,760**	70,000	**496,760**	160,000
Warranty provision	**10,542**	-	**14,136**	-
Others	**448,259**	434,549	**827,328**	1,157,011
	5,155,796	10,098,891	**15,038,957**	17,314,317

19 EARNINGS PER SHARE

The Company presents basic and diluted earnings per share (EPS) for its ordinary shares. Basic EPS is calculated by dividing the profit attributable to ordinary shareholders of the Company by the weighted average number of ordinary shares outstanding during the period.

	30 June 2026 (Unaudited) SR	*30 June 2025 (Unaudited) SR*	***30 June 2026 (Unaudited) SR***	*30 June 2025 (Unaudited) SR*
Profit attributable to shareholders of the Company	**9,995,256**	8,308,084	**26,662,380**	27,905,240
Weighted average number of shares	**7,000,000**	7,000,000	**7,000,000**	7,000,000
Basic and diluted earnings per share (SR per share)	**1.43**	1.19	**3.81**	3.99

20 FAIR VALUE OF ASSETS AND LIABILITIES

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either:

- In the principal market for the asset or liability; or
- In the absence of a principal market, in the most advantageous market for the asset or liability.

The principal or the most advantageous market must be accessible by the Company.

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest. A fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use.

The Company uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximising the use of relevant observable inputs and minimising the use of unobservable inputs.

All financial instruments for which fair value is recognised or disclosed are categorised within the fair value hierarchy, based on the lowest level input that is significant to the fair value measurement as a whole, as follows:

- Level 1: quoted (unadjusted) market prices in active markets for identical assets or liabilities.
- Level 2: valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable.
- Level 3: valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable.

If the inputs used to measure the fair value of an asset or liability falls into different levels of the fair value hierarchy, then the fair value measurement is categorized in its entirety in the same level of the fair value hierarchy as the lowest input level that is significant to the entire measurement.

The Company recognizes transfers between levels of the fair value hierarchy at the end of the reporting period during which the change has occurred. The management assessed that the fair value of cash and cash equivalents, trade receivables, instalment sales receivables. Short-term borrowings and trade payables approximate their carrying amounts largely due to the short-term maturities of these instruments.

During the six-month period ended 30 June 2026 and year ended 31 December 2025, there were no movements between the levels.

21 RELATED PARTY TRANSACTIONS AND BALANCES

Related parties are key shareholders, directors and key management personnel of the Company. The terms of these transactions have been approved by the Company's management. Key management personnel are those persons having authority and responsibility for planning, directing and controlling the activities of the Company, directly or indirectly, including Chief Executive Officer, Chief Financial Officer, Managing Director and others (whether executive or otherwise).

Following is the list of related parties and their transactions and the relationship with the Company.

Related Parties:	*Relationship*
Ali Mohammed Deeb Ali Eed	Major shareholder
Board of Directors and Audit Committee	Board and Committee members

Related party transactions mainly represent Salaries, allowances and bonuses of senior executives. The following are the most significant transactions with related parties and the resulting balances:

			Three-month period ended		***Six-month period ended***	
Related party	***Description of transaction***	***Relationship***	***30 June 2026 (Unaudited) SR***	*30 June 2025 (Unaudited) SR*	***30 June 2026 (Unaudited) SR***	*30 June 2025 (Unaudited) SR*
Audit Committee and Board of Directors	Remuneration	Audit Committee and Board of Directors	**360,000**	556,000	**360,000**	556,000

a) Remuneration of key management personnel:

Name	***Nature of transactions***	***30 June 2026 (Unaudited) SR***	*31 December 2025 (Audited) SR*
Key Management Personnel	Short-term employee benefits	**5,710,461**	3,138,951
	Post-employment benefits liability	**6,206,761**	5,764,392

22 PRIOR PERIOD ADJUSTMENT

Management has reassessed the classification of management incentive bonus and accordingly prior period management incentive amount of SR 3.26 million has been reclassified from selling and marketing expense to general and administrative expense. As a result of such reclassification, there is no impact on the unaudited interim condensed statement of financial position, unaudited interim condensed statement of changes in equity and unaudited interim condensed statement of cashflows.

Reclassification in the unaudited interim condensed statement of profit or loss and other comprehensive income for the period ended 30 June 2025 is summarised below:

	As previously reported	*Impact of reclassification*	*As currently reported*
Selling and marketing expense	21,346,026	(3,258,971)	18,087,055
General and administrative expense	14,055,346	3,258,971	17,314,317

23 EVENTS AFTER THE REPORTING PERIOD

Subsequent to the reporting date, geopolitical tensions in parts of the Middle East have increased. Public communications from government and regulatory authorities have continued to emphasise the resilience of the economy and the continuation of business operations across key sectors, supported by established business continuity and risk management frameworks.

These developments arose after the reporting period and have therefore been assessed as non-adjusting events in accordance with IAS 10 Events after the Reporting Period. Accordingly, no adjustments have been made to the amounts recognised in the interim condensed financial statements as at 30 June 2026, which reflect conditions existing at that date.

The Company has assessed the potential implications of these events on its operations, financial position and performance. Based on information currently available, including the continuation of core business activities, it is not practicable to reliably estimate the full financial effect of these non-adjusting events on future periods. Management has also considered the impact of these events on the Company's ability to continue as a going concern and has concluded that the going concern basis of preparation remains appropriate.

24 AUTHORISATION OF INTERIM CONDENSED FINANCIAL STATEMENTS

These interim condensed financial statements were authorised for issue by the Company's Board of Directors on 17 Rabi Al-Awwal 1448H (corresponding to 30 August 2026G).